腹主动脉瘤或外周动脉疾病筛查确诊男性的处方药物依从性:VIVA子研究
基于VIVA血管筛查试验的65-74岁男性队列,链接丹麦注册数据2007-2016年,分析腹主动脉瘤(AAA)或外周动脉疾病(PAD)确诊者抗血小板和他汀治疗的启动、持续与依从性。基线未用药者中约六成启动预防治疗,其5年依从率为57%-60%;基线已用药者5年依从率超过80%。
要点
- AAA或PAD筛查确诊的65-74岁男性中,基线未用药者仅约六成启动抗血小板或他汀治疗。
- 基线未用药且启动者的5年依从率仅57%-60%,提示筛查后预防用药落实不足。
- 基线已用药者5年依从率超过80%,但需关注筛查后120天内续方情况。
核心结论
- 在血管筛查试验中,每10名基线未用药者约有6名启动预防治疗,其中依从率为57%-60%。
- 基线已用药者5年抗血小板和他汀治疗依从率超过80%。
- 通过改善预防药物落实的措施可能提高筛查举措的有效性。
研究设计与样本
- 基于人群的队列研究,数据来自VIVA多面向心血管疾病筛查试验队列并链接丹麦注册数据(2007-2016年)。
- 研究对象为65-74岁在VIVA筛查中确诊AAA或PAD的男性,共识别618例AAA和2051例PAD。
- 筛查后120天内测量抗血小板和他汀治疗的启动;持续定义为两次续方间无超过100天的治疗缺口;5年随访期间覆盖天数比例≥80%作为依从性分类 cutoff。
主要发现
- 在18,748名筛查参与者中,识别出618例AAA和2051例PAD。
- 基线未用药者中,65%启动抗血小板治疗、62%启动他汀治疗;57%持续抗血小板使用、59%持续他汀使用;60%抗血小板依从、57%他汀依从。
- 基线已用药者中,73%在筛查后120天内续填抗血小板处方、69%续填他汀处方;79%持续抗血小板治疗、73%持续他汀治疗;89%抗血小板依从、83%他汀依从。
关键数值与推荐
- 启动测量窗口:筛查后120天内。
- 持续定义:两次续方间无治疗缺口>100天。
- 依从性分类 cutoff:5年随访期间覆盖天数比例≥80%。
临床怎么用
- 对筛查确诊AAA或PAD的老年男性,应主动评估并促进抗血小板和他汀治疗的启动与续方。
- 关注基线未用药者的启动率及启动后的长期依从性,采取措施减少治疗缺口。
- 对基线已用药者,确保筛查后120天内续方以维持高依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial. METHODS: This was a population based cohort study. The study population consisted of 65-74 year old men diagnosed with AAA or PAD in the Viborg Vascular (VIVA) multifaceted screening trial for CVD. Data from the VIVA screening cohort were linked to data from Danish registers from 2007 to 2016. Initiation of antiplatelet and statin treatment was measured within 120 days after screening. Persistence was defined as no treatment gap >100 days between two prescription renewals after screening. A proportion of days covered ≥80% over five years of follow up was used as a categorical cut off for adherence. RESULTS: Among the 18,748 screened participants, 618 with AAA and 2051 with PAD were identified. Among non-users at baseline, 65% and 62% initiated antiplatelet and statin treatment, 57% and 59% persisted with antiplatelet and statin use, and 60% and 57% were adherent, respectively. Among users at baseline, 73% and 69% had filled an antiplatelet or statin prescription, respectively, within 120 days after screening. Further, 79% and 73% persisted with their antiplatelet and statin treatment, and 89% and 83% were adherent, respectively. CONCLUSION: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57-60%. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80%. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication.
引用
- Qvist I, Søgaard R, Lindholt JS, et al. Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy. Eur J Vasc Endovasc Surg. 2018. PMID: 30393062. doi:10.1016/j.ejvs.2018.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。